Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo Therapeutics Inc Stock Quote: SGMO Stock News ... Nov 01, 2019 · SGMO, Sangamo Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Zacks Equity Research 03/04/2020 03:16 AM ET. Sangamo Therapeutics Announces Participation at … Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue ... Aug 07, 2019 · Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.17 per share a year ago. Sangamo Therapeutics, Inc. (SGMO) Stock Analysis & News ...
Join Stocktwits for free stock discussions, prices, and market sentiment with millions of $SGMO:US Sangamo Biosciences Upgraded to Hold by Zacks ( SGMO)
Sangamo Therapeutics - SGMO - Stock Price & News | The ... Real time Sangamo Therapeutics (SGMO) stock price quote, stock graph, news & analysis. Real time Sangamo Therapeutics (SGMO) stock price quote, stock graph, news & analysis. SGMO Stock Price, Forecast & News (Sangamo Therapeutics) 3 brokerages have issued 1-year price targets for Sangamo Therapeutics' shares. Their forecasts range from $10.00 to $16.00. On average, they expect Sangamo Therapeutics' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 107.0% from the stock's current price. View analysts' price targets for Sangamo Sangamo Therapeutics Inc. - NASDAQ:SGMO - Stock Quote ...
Find the latest Sangamo Therapeutics, Inc. (SGMO) stock quote, history, news and other vital information to help you with your stock trading and investing.
The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share. The drug developer posted revenue of $54.9 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $17 million.
Sangamo Therapeutics, Inc. - SGMO - Stock Price Today - Zacks
Sangamo Therapeutics (SGMO) Stock Price History | wallmine
Analyzing Sangamo Therapeutics (NASDAQ:SGMO) stock? View SGMO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC
SGMO Stock Price, Forecast & News (Sangamo Therapeutics)